EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MicroRNA-124-targeted recombinant Zika virus: a dual-functional and safe candidate for vaccination and oncolytic virotherapy

Chao Zhou, Meng-Li Cheng, Meng-Jiao He, Yao Liu, Yu-Yan Li, Dong-Yang Xie, Li-Shu Chen, De-Yu Li, Yong-Qiang Deng, Yan-Peng Xu, Qing Ye, Hui Zhao und 3 weitere

Journal of Virology · 2026

DOI: 10.1128/jvi.00208-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2026. Verfasst von Chao Zhou und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China. Hauptthemen laut MEDLINE: MicroRNAs, Zika Virus, Oncolytic Virotherapy, Zika Virus Infection. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Zika virus (ZIKV) remains a significant public health threat due to its pronounced neurotropism linked to Congenital Zika Syndrome (CZS). Paradoxically, the same neurotropism also provides a unique opportunity for exploiting ZIKV as an oncolytic agent against malignant brain tumors such as glioma. However, achieving precise control of ZIKV replication in specific cell types or tissues remains a major challenge. Here, we show that the brain-specific and enriched microRNA, miR-124, is highly expressed in neural progenitor cells (NPCs) and neurons, but minimally expressed in glioma stem cells (GSCs) and differentiated glioma stem cells (DGCs). Based on these observations, we engineered a recombinant ZIKV containing a miR-124 target sequence (miR-124T) inserted into the 3′ untranslated region (UTR) of the viral genome, generating the virus designated ZIKV-miR124T. ZIKV-miR124T exhibited a significantly attenuated phenotype across multiple mouse models, including adult A129 mice, BALB/c neonates, and pregnant mice. Importantly, in an orthotopic glioma model, ZIKV-miR124T retained potent oncolytic activity while showing a markedly improved safety profile. Viral replication was strictly confined in the tumor region, with a ~1,000-fold reduction in viral load in non-tumoral brain regions compared to the well-established live-attenuated ZIKV (ZIKV-LAV). Furthermore, a single immunization with ZIKV-miR124T conferred effective protection against lethal ZIKV challenge and significantly reduced vertical transmission in pregnant mice. Collectively, our findings establish a strong proof of concept for a rational, miRNA-guided strategy to generate a next-generation ZIKV platform with dual potential as a safe live-attenuated vaccine and a precisely regulated oncolytic virus. IMPORTANCE This study presents a crucial advancement in controlling the safety and function of neurotropic viruses. We engineered a dual-purpose ZIKV, ZIKV-miR124T, which is regulated by the brain-specific microRNA, miR-124. This design forces the virus to strongly self-suppress in healthy neural tissue, solving a major safety concern for ZIKV-based therapies. ZIKV-miR124T is shown to be a potent oncolytic agent against malignant glioma while also serving as a highly effective, safe live-attenuated vaccine against ZIKV infection, reducing vertical transmission to the fetus. Our work provides a strong demonstration of utilizing microRNA regulation to achieve precise viral tropism and attenuation, offering a valuable, generalizable strategy for the development of safer and more effective viral therapies and vaccines against neurotropic pathogens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsZika VirusOncolytic VirotherapyZika Virus InfectionOncolytic VirusesAnimalsMiceFemaleHumansMice, Inbred BALB CVirus ReplicationPregnancyVaccinationNeural Stem CellsGliomaDisease Models, AnimalBrain Neoplasms

Stichwörter der Autor:innen

Zika virusgliomalive attenuated vaccinemicroRNA-124oncolytic virus

Substanzen

MicroRNAs

Autor:innen und Institutionen

  • State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China.
  • Experimental Platform Management Office, Beijing Key Laboratory of Drug-Resistant Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
  • State Key Laboratory of Proteomics, National Center of Biomedical Analysis, Beijing, China.

ORCID-Profile: Xiao-Feng Li, Qi Chen, Cheng-Feng Qin

Zitieren

APA

Zhou, C., Cheng, M. L., He, M. J., Liu, Y., Li, Y. Y., Xie, D. Y., Chen, L. S., Li, D. Y., Deng, Y. Q., Xu, Y. P., Ye, Q., Zhao, H., Li, X. F., Chen, Q., & Qin, C. F. (2026). MicroRNA-124-targeted recombinant Zika virus: a dual-functional and safe candidate for vaccination and oncolytic virotherapy. Journal of Virology. https://doi.org/10.1128/jvi.00208-26

Vancouver

Zhou C, Cheng ML, He MJ, Liu Y, Li YY, Xie DY, et al. MicroRNA-124-targeted recombinant Zika virus: a dual-functional and safe candidate for vaccination and oncolytic virotherapy. Journal of Virology. 2026. doi:10.1128/jvi.00208-26

BibTeX
@article{Zhou2026,
  author = {Zhou, Chao and Cheng, Meng-Li and He, Meng-Jiao and Liu, Yao and Li, Yu-Yan and Xie, Dong-Yang and Chen, Li-Shu and Li, De-Yu and Deng, Yong-Qiang and Xu, Yan-Peng and Ye, Qing and Zhao, Hui and Li, Xiao-Feng and Chen, Qi and Qin, Cheng-Feng},
  title = {MicroRNA-124-targeted recombinant Zika virus: a dual-functional and safe candidate for vaccination and oncolytic virotherapy},
  journal = {Journal of Virology},
  year = {2026},
  doi = {10.1128/jvi.00208-26}
}
Kostenlos starten →